Brief: Biomx Announces Completion Of Patient Dosing In Part 2 Of The Phase 1B/2A Study Evaluating Bx004 For Treatment Of Chronic Pulmonary Infections In Patients With Cystic Fibrosis

Tessera Defense and Homeland Security

04/10/2023 11:40

Oct 4 (Reuters) - Biomx Inc  PHGE.A :
    * BIOMX ANNOUNCES COMPLETION OF PATIENT DOSING IN PART 2 OF
THE
PHASE 1B/2A STUDY EVALUATING BX004 FOR TREATMENT OF CHRONIC
PULMONARY INFECTIONS IN PATIENTS WITH CYSTIC FIBROSIS
    * BIOMX INC - COMPANY REMAINS ON TRACK TO REPORT PART 2
RESULTS
FROM STUDY IN NOVEMBER 2023

Source text for Eikon:  ID:nGNX7Z3C6z 
Further company coverage:  PHGE.A 

 ((Reuters.Briefs@thomsonreuters.com))